Active, not recruitingPhase 2NCT06444451
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
Studying Alopecia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Amlitelimab(drug)
- Enrollment
- 166 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Total Skin and Beauty Dermatology Center- Site Number : 8400018, Birmingham, Alabama, United States
- First OC Dermatology- Site Number : 8400014, Fountain Valley, California, United States
- Center for Dermatology Clinical Research- Site Number : 8400008, Fremont, California, United States
- UC Irvine Healthcare - Gottschalk Medical Plaza- Site Number : 8400007, Irvine, California, United States
- Dermatology Research Associates - Los Angeles- Site Number : 8400015, Los Angeles, California, United States
- New Horizon Research Center- Site Number : 8400017, Miami, Florida, United States
- Dawes Fretzin Clinical Research- Site Number : 8400010, Indianapolis, Indiana, United States
- Michigan Center for Research Company- Site Number : 8400016, Clarkston, Michigan, United States
- Joel Schlessinger, PC- Site Number : 8400021, Omaha, Nebraska, United States
- Icahn School of Medicine at Mount Sinai- Site Number : 8400003, New York, New York, United States
- DJL Clinical Research - Charlotte - Park Road- Site Number : 8400013, Charlotte, North Carolina, United States
- Cleveland Clinic- Site Number : 8400028, Cleveland, Ohio, United States
- Apex Clinical Research Center- Site Number : 8400027, Mayfield Heights, Ohio, United States
- Vital Prospects Clinical Research Institute - Tulsa- Site Number : 8400004, Tulsa, Oklahoma, United States
- Oregon Medical Research Center- Site Number : 8400002, Portland, Oregon, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06444451 on ClinicalTrials.govOther trials for Alopecia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07487948Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07533006A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)Eli Lilly and Company
- ENROLLING BY INVITATIONNCT07499713Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia AreataIstanbul Training and Research Hospital
- RECRUITINGPHASE3NCT07435012Androgenic Alopecia TH07 Clinical TrialTriple Hair Inc
- RECRUITINGNANCT07422376Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands RegionCharles Mays
- RECRUITINGNCT07226531Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USPfizer
- RECRUITINGNANCT07563036JAK2 Expression in Androgenetic Alopecia Before and After Topical MinoxidilKasr El Aini Hospital
- RECRUITINGPHASE2NCT07370519Topical Application of Lactobacillus Reuteri for Androgenetic AlopeciaShenzhen People's Hospital